Nordicus Partners Corp
nordicuspartners.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Nordicus Partners, a pre-revenue biotech holding company, reported a widening quarterly net loss of $2.3 million driven largely by a $1.49 million fair value write-down of its investment in Mag Mile Capital, and ended the quarter with only $5,784 in cash against $1.67 million in current liabilities. The company is increasingly reliant on related-party notes payable to fund operations, disclosure controls were deemed not effective, and stockholders' equity declined from $64.2 million to $61.5 million quarter-over-quarter, raising going-concern-level liquidity concerns.
Red Flags Detected (9)
Cash balance of only $5,784 as of June 30, 2026, down from $20,878, against current liabilities of $1.67 million — severe liquidity shortfall
Working capital deficit: total current assets of $298,402 vs. total current liabilities of $1,666,775
Investment in Mag Mile Capital, Inc. written down from $2,250,000 to $763,000, a $1,487,000 fair value loss in a single quarter (following a $375,000 loss in the prior-year quarter)
6 more red flags detected
Key Takeaways
Company remains a pre-revenue biotech holding vehicle with three preclinical Danish portfolio companies (Orocidin A/S, Bio-Convert A/S, NoviThera ApS)
Balance sheet is dominated by intangible assets (IPR&D and goodwill) with no revenue to validate carrying values, creating impairment risk
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.